Neoadjuvant Chemotherapy Alone or Combined with EGFR-Directed Targeted Therapy or Anti-PD-1 Immunotherapy for Locally Advanced Lacrimal Sac and Nasolacrimal Duct Carcinomas

CONCLUSIONS: Neoadjuvant systemic therapy can shrink tumors in patients with locally advanced primary lacrimal sac/NLD carcinoma with orbital or skull base invasion.PMID:38500295 | DOI:10.1080/08820538.2024.2324057

Source: Seminars in Ophthalmology - March 19, 2024 Category: Opthalmology Authors: Jeremy Goldfarb Janet Fan Luana Guimaraes de Sousa Neal Akhave Jeffrey Myers Ryan Goepfert Krish Manisundaram Jiawei Zhao Steven J Frank Amy Moreno Renata Ferrarotto Bita Esmaeli Source Type: research